<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10945491</article-id><article-id pub-id-type="pmc">2374647</article-id><article-id pub-id-type="pii">6691295</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1295</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kollmannsberger</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Quietzsch</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Haag</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lingenfelser</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Schroeder</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Hartmann</surname><given-names>J T</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Baronius</surname><given-names>W</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hempel</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Clemens</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Kanz</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bokemeyer</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Hematology/Oncology, University of Tuebingen Medical Center, Tuebingen</aff><aff id="aff2"><label>2</label>Department of Internal Medicine II, Klinikum Chemnitz, Chemnitz</aff><aff id="aff3"><label>3</label>Department of Hematology/Oncology/Gastroenterology, University of Dresden, Dresden</aff><aff id="aff4"><label>4</label>Department of Gastroenterology, Horst-Schmidt-Kliniken, Wiesbaden</aff><aff id="aff5"><label>5</label>Department of Hematology/Oncology, St. Johannes-Hospital, Duisburg</aff><aff id="aff6"><label>6</label>Department of Internal Medicine, Krankenanstalt der Boromaeerinnen Trier, Germany</aff><pub-date pub-type="epub"><day>24</day><month>07</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>07</month><year>2000</year></pub-date><volume>83</volume><issue>4</issue><fpage>458</fpage><lpage>462</lpage><history><date date-type="received"><day>25</day><month>01</month><year>2000</year></date><date date-type="rev-recd"><day>17</day><month>04</month><year>2000</year></date><date date-type="accepted"><day>25</day><month>04</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel, cisplatin and 24 h continuous infusion of 5-FU/folinic acid in patients (pts) with unresectable, locally advanced or metastatic gastric adenocarcinoma. Forty-five chemotherapy-naive pts (28 male and 17 female) with a median age of 60 years (range 35&#x02013;74) were enrolled. 5-FU 2 g/m<sup>2</sup>was given weekly over 24 h i.v. preceded by folinic acid 500 mg/m<sup>2</sup>as a 2 h infusion. Paclitaxel 175 mg/m<sup>2</sup>was administered as a 3 h-infusion on days 1 and 22 and cisplatin 50 mg/m<sup>2</sup>as 1 h infusion on days 8 and 29. Six weeks of therapy (days 1, 8, 15, 22, 29, 36) followed by 2 weeks rest were considered one cycle. A median of 3 cycles (range 1&#x02013;4) were administered to 45 pts assessable for response, survival and toxicity. Five pts (11&#x00025;) obtained a CR and 18 pts (40&#x00025;) a PR (ORR 51&#x00025;; 95&#x00025; Cl: 35.8&#x02013;66.3&#x00025;). Responses were achieved in the liver, lymph nodes, lungs and at the site of the primary tumour. Nine pts (20&#x00025;) had stable disease. Thirteen pts (29&#x00025;) were considered to have failed treatment, 8 pts (18&#x00025;) due to progressive disease and 5 pts (11&#x00025;) who did not receive one complete cycle of therapy due to acute non-haematologic toxicity. The median progression-free and overall survival times were 9 months (range 1&#x02013;36+) and 14 months (range 2&#x02013;36+), respectively. Neutropenia WHO III&#x000b0;/IV&#x000b0; occurred in 7 pts (15&#x00025;) with only 1 pt having grade IV. Additional non-haematologic WHO III&#x000b0;/IV&#x000b0; toxicities included nausea/vomiting in 5 (11&#x00025;), alopecia in 22 (49&#x00025;), and diarrhoea in 1 patient each (2&#x00025;). Dose reductions or treatment delays were necessary in 8 pts (17&#x00025;), mainly due to neutropenia. All pts were treated on an outpatient basis. The combination of paclitaxel, cisplatin and continuously infused 5-FU/folinic acid appears to be a highly active regimen for the treatment of pts with advanced gastric cancer. While the overall acceptable toxicity allows its use in the palliative setting, it may also be an attractive option to be tested for neoadjuvant or adjuvant treatment. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>gastric cancer</kwd><kwd>metastatic</kwd><kwd>chemotherapy</kwd><kwd>paclitaxel</kwd><kwd>continuous infusion</kwd></kwd-group></article-meta></front></article>


